Effects of weight loss with blood lipid-lowering medication on blood lipid concentratio
Not Applicable
Recruiting
- Conditions
- overweight and obesity.overweight and obesity
- Registration Number
- IRCT20160702028742N10
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
BMI>25 kg/m2
No weight change of more than 1-2 kg in the past month
LDL-C less than 130 mg/dL
Taking statins for more than 2 months (participants in the statin group)
Exclusion Criteria
chronic chronic kidney disease (Cr> 1.4 mg / dl), cancer, autoimmune or inflammatory diseases treated with corticosteroids
Pregnancy and lactation
Regular use of garlic pills, omega-3 supplements, or flaxseed
Changes in medications during the study period
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma total cholesterol to HDL-cholesterol ratio. Timepoint: Baseline and after 2 months. Method of measurement: Enzymatic.
- Secondary Outcome Measures
Name Time Method Plasma LDL-C. Timepoint: Baseline and after 2 moths. Method of measurement: Enzymatic.;Plasma TG. Timepoint: Baseline and after 2 moths. Method of measurement: Enzymatic.;CRP. Timepoint: Baseline and after 2 moths. Method of measurement: Turbidometry.;IL-6. Timepoint: Baseline and after 2 moths. Method of measurement: ELISA.;Plasminogen activator inhibitor-1. Timepoint: Baseline and after 2 moths. Method of measurement: ELISA.;Apolipoprotein B. Timepoint: Baseline and after 2 moths. Method of measurement: Turbidometry.